摘要
目的:研究赤芍总苷对肺癌大鼠肺组织的作用机制。方法:将大鼠分为正常组、模型组和赤芍总苷组,观察3组大鼠体质量的变化情况,比较3组大鼠肺指数和肺组织形态变化,及大鼠肺组织中存活素(Survivin)、鼠类肉瘤病毒癌基因(KRAS)表达及mRNA的表达。结果:在同一时间点,3组大鼠的体质量比较差异无统计学意义(P<0.05)。对3组大鼠的体质量增长幅度比较,赤芍总苷组大鼠显著高于模型组,并且赤芍总苷组大鼠的末期体质量也显著重于模型组大鼠,差异有统计学意义(P<0.05)。与正常组大鼠肺指数比较,模型组显著升高(P<0.05),同时肺组织出现了明显的恶化;与模型组比较,赤芍总苷组大鼠的肺指数显著降低(P<0.05),并且肺组织得到了显著的改善(P<0.05)。3组大鼠的Survivin和Kras比较,模型组阳性表达显著增多,mRNA表达也显著高于正常组(P<0.05);赤芍总苷组大鼠的阳性表达和mRNA表达都显著低于模型组(P<0.05)。结论:赤芍总苷可有效抑制肺癌大鼠肺组织中Survivin和KRAS基因的表达,同时抑制微血管的生成。
Objective:To study the mechanism of total glucosides of paeony(TGP)on lung tissue of rats with lung cancer.Methods:The rats were divided into a normal group,a model group and a total paeony glycosides group.The body mass changes of the 3 groups were observed.The lung index and lung tissue morphology changes of the three groups were compared,and the survivin in the lung tissue of the rats was compared(Survivin),Kirsten rat sarcoma viral oncogene(KRAS)expression and mRNA expression.Results:There was no significant difference in the weight of the 3 groups at the same time(P<0.05).Compared with the three groups of rats,the weight gain of TGP group was significantly higher than that of model group,and the final weight of TGP group was also significantly heavier than that of model group(P<0.05).Compared with the normal group,the lung index of the model group increased significantly(P<0.05),and the lung tissue deteriorated significantly;compared with the model group,the lung index of the TGP group decreased significantly(P<0.05),and the lung tissue improved significantly(P<0.05).The positive expression of Survivin and KRAS in the model group was significantly increased in the three groups,and the mRNA expression in the group was significantly higher than that in the normal group(P<0.05);the positive expression and mRNA expression in the TGP group were significantly lower than that in the model group(P<0.05).Conclusion:TGP can effectively inhibit the expression of Survivin and KRAS genes in lung tissue of lung cancer rats,and inhibit the angiogenesis.
作者
辜正策
邓小婧
李璐池
GU Zhengce;DENG Xiaojing;LI Luchi(Department of Pathology,Meishan Hospital of Traditional Chinese Medicine,Meishan 620010,China)
出处
《世界中医药》
CAS
2022年第2期177-181,共5页
World Chinese Medicine
基金
四川省科技计划重点研发项目(20ZDYF2528)。
